These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1606075)

  • 41. Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
    Bojic M; Schmidinger M
    Clin Genitourin Cancer; 2012 Dec; 10(4):277-9. PubMed ID: 22658385
    [No Abstract]   [Full Text] [Related]  

  • 42. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 43. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
    Shaheen PE; Stadler W; Elson P; Knox J; Winquist E; Bukowski RM
    Invest New Drugs; 2005 Dec; 23(6):577-81. PubMed ID: 16034517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study.
    Stoter G; Fosså SD; Rugarli C; Symann M; Jasmin C; Israel L; Bijman JT; Palmer P; Franks CR; Philip T
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():111-3. PubMed ID: 2670207
    [No Abstract]   [Full Text] [Related]  

  • 45. Phase I-II trial of gallium nitrate for advanced hypernephroma.
    Schwartz S; Yagoda A
    Anticancer Res; 1984; 4(4-5):317-8. PubMed ID: 6486736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
    Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI
    Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
    Hutson TE
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy of metastatic renal cancer.
    Denis L; Van Oosterom A
    Semin Surg Oncol; 1988; 4(2):91-4. PubMed ID: 3293156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
    Stahl M; Schmoll E; Becker H; Schlichter A; Hoffmann L; Wagner H; Possinger K; Müller W; Köllermann M; Weidenhammer W
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):33-7. PubMed ID: 2031196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complete response in metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical case and review of the literature.
    Detti B; Francolini G; Becherini C; Olmetto E; Giacomelli I; Scartoni D; Greto D; Baldazzi V; Simontacchi G; Meattini I; Livi L
    J Chemother; 2016 Oct; 28(5):432-4. PubMed ID: 27376403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose regimen of interleukin-2 for metastatic renal carcinoma.
    Sleijfer DT; Janssen RA; Willemse PH; Martens A; de Leij L; de Vries EG; Mulder NH
    Lancet; 1990 Jun; 335(8704):1522-3. PubMed ID: 1972445
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.
    Allen A; Wolf M; Crawford ED; Davis MP; Natale RB; Barnett ML
    Invest New Drugs; 1992 Jul; 10(2):129-32. PubMed ID: 1500267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Will we be able to "cure" metastatic renal cell carcinoma like we cure testicular tumours?
    Kirkali Z
    Eur Urol; 2008 Oct; 54(4):712-4. PubMed ID: 18640767
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II trial of streptozocin in the treatment of advanced renal cell carcinoma.
    Licht JD; Garnick MB
    Cancer Treat Rep; 1987 Jan; 71(1):97-8. PubMed ID: 2947680
    [No Abstract]   [Full Text] [Related]  

  • 56. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
    Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
    Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
    Amato R
    Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
    [No Abstract]   [Full Text] [Related]  

  • 58. Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.
    Valls L; Hoimes C; Sher A; Hu L; Lee Z; Muzic R; Avril N
    Semin Roentgenol; 2014 Jul; 49(3):238-41. PubMed ID: 25497908
    [No Abstract]   [Full Text] [Related]  

  • 59. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
    Mansueto G; Longo F
    Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase II study of cystemustine in advanced renal cancer.
    Chauvergne J; Kerbrat P; Adenis A; Chollet P; Fargeot P; Pujade-Lauraine E; Dieras V; Madelmont JC; Lentz MA; Toulouse C
    Eur J Cancer; 1995; 31A(1):130-1. PubMed ID: 7695969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.